Goldman Sachs Upgrades Agilent, Bruker; Lowers Cepheid, LabCorp | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs has upgraded the stock of Agilent Technologies and Bruker, but downgraded Cepheid and Laboratory Corporation of America.

In a report released Sunday about the impending fiscal cliff as well as the global macroeconomic picture, analyst Isaac Ro upgraded the stocks of both Agilent and Bruker to a Buy rating from Neutral, but lowered Cepheid to Neutral from Buy and LabCorp to Sell from Neutral.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.